Who
Ryan D. Maynard
Director
Company insider
Files Form 4 as: Director, Iovance Biotherapeutics; Chief Financial Officer, Foghorn Therapeutics; Chief Financial Officer, Tvardi Therapeutics; EVP & CFO, Rigel Pharmaceuticals.
In numbers
- Trades disclosed
- 63
- Buys
- 1
- Sells
- 8
- Bought
- $51K
- Sold
- $2.0M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 7 Aug 2006
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,316 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,316 at $0.00 | filing |
| 23 Feb 2026filed 24 Feb 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.3M400,000 at $5.75 | filing |
| 23 Feb 2026filed 24 Feb 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $2.3M400,000 at $5.75 | filing |
| 13 Jun 2025filed 17 Jun 2025 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,546 at $0.00 | filing |
| 12 Nov 2024filed 14 Nov 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 12 Nov 2024filed 14 Nov 2024 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $373K50,000 at $7.45 | filing |
| 12 Nov 2024filed 14 Nov 2024 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $503K50,000 at $10.06 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,303 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | TVRD Tvardi TherapeuticsBiotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,955 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 8 Feb 2023filed 12 Feb 2024 | TVRD Tvardi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,9095,488 at $0.53 | filing |
| 12 Sep 2022filed 14 Sep 2022 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 10 Jun 2022filed 14 Jun 2022 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,204 at $0.00 | filing |
| 31 May 2022filed 2 Jun 2022 | IOVA Iovance BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $51K7,500 at $6.75 | filing |
| 29 Jun 2021filed 1 Jul 2021 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 8 Jun 2020filed 10 Jun 2020 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 10 Jun 2019filed 11 Jun 2019 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
Ascendis Pharma A/S (NASDAQ:ASND) vs. Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head ReviewRIGL · tickerreport.com · 21 Oct 2026Undercovered Stocks: Hess Midstream, Iovance Biotherapeutics, Netlist, And MoreIOVA · seekingalpha.com · 19 Oct 2026Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)IOVA · tickerreport.com · 15 Oct 2026Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $11.00IOVA · themarketsdaily.com · 11 Oct 2026Contrasting Phibro Animal Health (NASDAQ:PAHC) and Tvardi Therapeutics (NASDAQ:TVRD)TVRD · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Ryan D. Maynard; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.